AbbVie will invest $195 million in its North Chicago, Illinois, manufacturing plant to expand domestic active pharmaceutical ingredient (API) production in the U.S. The new North Chicago API facility will expand AbbVie’s chemical synthesis capabilities in the U.S., supporting domestic production of current and next-generation neuroscience, immunology and oncology medicines. This expansion is part of AbbVie’s previously announced commitment to invest more than $10 billion of cap...